PDD's 5 Billion Yuan Investment and 5,000 Jobs: What's Being Built in Xiong'an?

Intellia reports Phase 3 trial shows lonvo-z cuts hereditary angioedema attacks 87% vs placebo

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (Lonvo-Z) in Patients With Hereditary Angioedema

Intellia Therapeutics - Initiates Rolling Bla Submission for Lonvo-Z; U.S. Launch Expected First Half 2027

Intellia Therapeutics - Haleo Met Its Primary Endpoint With an 87% Reduction (P<0.0001) in Mean Monthly Attacks in Lonvo-Z Arm

Exploring the Culinary Battle at Leilei Night Market: Shenyang Flavors Versus Fushun Tastes

Blue Moon Group Reports Over HK$1 Billion in Losses Over Two Years, While Executive Pay Rises to HK$47.97 Million, Dividends Exceed Cumulative Net Profit

Li Auto Executive Outlines Vision for the Next Decade: A Shift from Features to Life

J&J - Talvey Plus Darzalex Faspro Shows Consistent Safety Profile and Reduced Severe Infections

Hohhot Launches Vehicle Purchase Subsidy Program with Payouts from 3,000 to 6,000 Yuan

Incyte says Phase 3 frontMIND trial shows tafasitamab combo cuts lymphoma progression or death risk 25%

Results From Incyte’s Pivotal Phase 3 Frontmind Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (Eha) Congress Plenary Showed Prolonged Progression Free Survival

RPT-With smooth SpaceX debut, Wall Street sets new template for mega IPOs